Skip to main content
Log in

Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma

  • Original article
  • Published:
Japanese Journal of Radiology Aims and scope Submit manuscript

Abstract

Purpose

To compare local control effects of superselective transcatheter arterial chemoembolization (TACE) using epirubicin (EPI) plus mitomycin C (M) and miriplatin (MPT) for hepatocellular carcinoma (HCC).

Materials and methods

One-hundred and twenty-nine HCCs treated with superselective TACE were divided into three groups according to the type of anticancer drug; EPI-M-TACE (n = 51), MPT-TACE (n = 21), and MPT-I-TACE (MPT emulsion) (n = 57). Local recurrence, patterns of recurrence (intratumoral recurrence; IR), and follow-up angiograms were evaluated.

Results

Mean tumor diameter and follow-up period for the EPI-M-TACE, MPT-TACE, and MPT-I-TACE groups were 16.9 mm and 15.5 months, 20.7 mm and 12.0 months, and 18.8 mm and 9.6 months, respectively. Local recurrence for the EPI-M-TACE, MPT-TACE, and MPT-I-TACE groups at 5, 10, and 15 months was 6.1, 47.6, and 40.1%, 23.5, 67.3, and 63.9%, and 26.2, 75.4, and 72.9%, respectively. IR for the EPI-M-TACE, MPT-TACE, and MPT-I-TACE groups was 23.1, 71.4, and 71.0%, respectively. Local recurrence and IR in the EPI-M-TACE group were significantly less than those in the MPT-TACE and MPT-I-TACE groups. Follow-up angiograms revealed less arterial damage in the MPT-TACE and MPT-I-TACE groups.

Conclusion

Superselective TACE using MPT resulted in very frequent local recurrence, in particular IR, despite less arterial damage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983;148:397–401.

    PubMed  CAS  Google Scholar 

  2. Uchida H, Ohishi H, Matsuo N, Nishimine K, Ohue S, Nishimura Y, et al. Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and Gelfoam particles for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 1990;13:140–5.

    Article  PubMed  CAS  Google Scholar 

  3. Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology. 1993;188:79–83.

    PubMed  CAS  Google Scholar 

  4. Miyayama S, Matsui O, Yamashiro M, Ryu Y, Kaito K, Ozaki K, et al. Ultraselective transcatheter arterial chemoembolization with a 2-F tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Raiol. 2007;18:365–76.

    Article  Google Scholar 

  5. Kishimoto S, Noguchi T, Yamaoka T, Fukushima S, Takeuchi Y. In vitro release of SM-11355, cis[((1R, 2R)-1,2-cyclohexanediamine-N,N’)bis(myristato)] platinum(II) suspended in lipiodol. Biol Pharm Bull. 2000;23:637–40.

    Article  PubMed  CAS  Google Scholar 

  6. Hamada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N, et al. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors inplanted in rat livers by including platinum-DNA adducts to form and massive apotosis. Cancer Chemother Pharmacol. 2009;64:473–83.

    Article  Google Scholar 

  7. Okusaka T, Okada S, Nakanishi T, Fujiyama S, Kubo Y. Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs. 2004;22:169–76.

    Article  PubMed  CAS  Google Scholar 

  8. Ikeda K, Okusaka T, Ikeda M, Morimoto M. Transcatheter arterial chemoembolization with a lipophilic platinum complex SM-11335 (miriplatin hydrate)—safety and efficacy in combination with embolizing agents. Jpn J Cancer Chemother. 2010;37:271–5 (in Japanese).

    Google Scholar 

  9. Cammà C, Schepis F, Orlando A, Albansese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trial. Radiology. 2002;224:47–54.

    Article  PubMed  Google Scholar 

  10. Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma—a comparison of lipiodol-transcatheter arterial embolizaion with and without adriamycin (first cooperative study). Cancer Chemother Pharmacol. 1992;31 Suppl:s1–6.

    Google Scholar 

  11. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010;33:541–51.

    Article  PubMed  Google Scholar 

  12. Kamada K, Nakanishi T, Kitamoto M, Aikata H, Kawakami Y, Ito K, et al. Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol. 2001;12:847–54.

    Article  PubMed  CAS  Google Scholar 

  13. Kasai K, Ushio A, Sawara K, Miyamoto Y, Kasai Y, Oikawa K, et al. Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma. World J Gastroenterol. 2010;16:3437–44.

    Article  PubMed  CAS  Google Scholar 

  14. Yodono H, Matsuo K, Shinohara A. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma. Anti-Cancer Drugs. 2011;22:277–82.

    Article  PubMed  CAS  Google Scholar 

  15. Kawaoka T, Aikata H, Katamura Y, Takaki S, Waki K, Hiramatsu A, et al. Hypersensitivity reactions to transcatheter chemoembolization with cisplatin and lipiodol suspension for unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2010;21:1219–25.

    Article  PubMed  Google Scholar 

  16. de Baere T, Zhang X, Aubert B, Harry G, Lagrange C, Ropers J, et al. Quantification of tumor uptake of iodized oils and emulsions of iodized oils: experimental study. Radiology. 1996;201:731–5.

    PubMed  Google Scholar 

  17. Demachi H, Matsui O, Abo H, Tatsu H. Simulation model based on non-Newtonian mechanics applied to the evaluation of the embolic effect of emulsions of iodized oil and anticancer drug. Cardiovasc Intervent Radiol. 2000;23:285–90.

    Article  PubMed  CAS  Google Scholar 

  18. Lewis AL, Gonzalez MV, Lloyd AW, Hall B, Tang Y, Willis SL, et al. DC Bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol. 2006;17:335–42.

    Article  PubMed  Google Scholar 

  19. Varela M, Real MI, Burrel M, Former A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474–81.

    Article  PubMed  CAS  Google Scholar 

  20. Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K. Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy. Cancer Chemother Pharmacol. 1989;23 Suppl:s4–8.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Shiro Miyayama.

About this article

Cite this article

Miyayama, S., Yamashiro, M., Shibata, Y. et al. Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma. Jpn J Radiol 30, 263–270 (2012). https://doi.org/10.1007/s11604-011-0043-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11604-011-0043-6

Keywords

Navigation